Disposition of Delta tetrahydrocannabinol in CF1 mice deficient in mdr1a P-glycoprotein.
- Authors
- Bonhomme-Faivre, Laurence; Benyamina, Amine; Reynaud, Michel; Farinotti, Robert; Abbara, Chadi
- Year
- 2008
- Journal
- Addiction biology
- PMID
- 18331373
- DOI
- 10.1111/j.1369-1600.2008.00096.x
P-glycoprotein (P-gp) plays a major role in drug efflux. All the transported substrates are more or less hydrophobic and amphiphatic in nature. Being lipophilic, Delta(9) tetrahydrocannabinol (THC), the main cannabis component, could be a potential P-gp substrate. The aim of this project was to determine the contribution of the mdr1a gene product to THC disposition. Therefore, oral THC and digoxin (substrate test for P-gp) pharmacokinetics have been investigated in the intestinal epithelium and in the brain capillary endothelium of CF1 mdr1a-/- mice (mice naturally deficient in P-gp). These pharmacokinetics were compared to THC and digoxin oral pharmacokinetics in wild type mice mdr1a+/+ (not P-gp deficient). The application of Bailer's method showed that THC total exposure measured by the area under the plasma concentration time curve was 2.17-fold higher in CF1 mice naturally deficient in P-gp than in wild type mice after oral administration of 25 mg/kg of THC, and 2.4-fold higher after oral administration of 33 microg/kg of digoxin. As a consequence, the oral bioavailability of THC and digoxin was higher in naturally P-gp-deficient mice. We concluded that P-gp limits THC oral uptake and mediates direct drug excretion from the systemic circulation into the intestinal lumen.
No figures extracted from this document.
No chunks β full text not yet ingested.
No entities extracted from this document yet.
No uploaded files.
No citations found.
In this knowledge base
| Title | Year | PMID |
|---|---|---|
| The genetic epidemiology of substance use disorder: A review. | 2017 | 28938182 |
External
| Title | Authors | Journal | Year | Link |
|---|---|---|---|---|
| Elucidating the role of ABC transporters in the placental efflux of (-)- Ξ<sup>9</sup>-tetrahydrocannabinol (THC) using a cocktail of ABC transport inhibitors. | Balhara A et al. | β | 2026 | β |
| Efflux transporters in drug disposition during pregnancy. | Chen X et al. | β | 2025 | β |
| Are Ξ<sup>9</sup>-Tetrahydrocannabinol and Its Major Metabolites Substrates or Inhibitors of Placental or Human Hepatic Drug Solute-Carrier Transporters? | Chen X et al. | β | 2024 | β |
| CBD and THC in Special Populations: Pharmacokinetics and Drug-Drug Interactions. | Qian L et al. | β | 2024 | β |
| How Biodegradable Polymers Can be Effective Drug Delivery Systems for Cannabinoids? Prospectives and Challenges. | Sobieraj J et al. | β | 2024 | β |
| The impact of pregnancy and associated hormones on the pharmacokinetics of Ξ<sup>9</sup>-tetrahydrocannabinol. | Authement AK et al. | β | 2024 | β |
| Maternal and Fetal Exposure to (-)-Ξ<sup>9</sup>-tetrahydrocannabinol and Its Major Metabolites in Pregnant Mice Is Differentially Impacted by P-glycoprotein and Breast Cancer Resistance Protein. | Chen X et al. | β | 2023 | β |
| Nanoformulations as a strategy to overcome the delivery limitations of cannabinoids. | Reddy TS et al. | β | 2023 | β |
| THC and CBD: Similarities and differences between siblings. | Stella N | β | 2023 | β |
| Understanding the Mechanism and Extent of Transplacental Transfer of (-)-β<sup>9</sup> -Tetrahydrocannabinol (THC) in the Perfused Human Placenta to Predict In Vivo Fetal THC Exposure. | Kumar AR et al. | β | 2023 | β |
| Association between <i>ABCB1</i> rs2235048 Polymorphism and THC Pharmacokinetics and Subjective Effects following Smoked Cannabis in Young Adults. | Matheson J et al. | β | 2022 | β |
| In vitro evaluation of the interaction of the cannabis constituents cannabichromene and cannabichromenic acid with ABCG2 and ABCB1 transporters. | Etchart MG et al. | β | 2022 | β |
| Review of delta-8-tetrahydrocannabinol (Ξ<sup>8</sup> -THC): Comparative pharmacology with Ξ<sup>9</sup> -THC. | Tagen M et al. | β | 2022 | β |
| Development and Verification of a Linked <i>Ξ</i> <sup>9</sup>-THC/11-OH-THC Physiologically Based Pharmacokinetic Model in Healthy, Nonpregnant Population and Extrapolation to Pregnant Women. | Patilea-Vrana GI et al. | β | 2021 | β |
| Tetrahydrocannabinol and Its Major Metabolites Are Not (or Are Poor) Substrates or Inhibitors of Human P-Glycoprotein [ATP-Binding Cassette (ABC) B1] and Breast Cancer Resistance Protein (ABCG2). | Chen X et al. | β | 2021 | β |
| Cannabinoids, Blood-Brain Barrier, and Brain Disposition. | Calapai F et al. | β | 2020 | β |
| A marijuana-drug interaction primer: Precipitants, pharmacology, and pharmacokinetics. | Cox EJ et al. | β | 2019 | β |
| ABCB1 C3435T polymorphism is associated with tetrahydrocannabinol blood levels in heavy cannabis users. | Kebir O et al. | β | 2018 | β |
| Cannabis and anticancer drugs: societal usage and expected pharmacological interactions - a review. | BouquiΓ© R et al. | β | 2018 | β |
| Piperine-pro-nanolipospheres as a novel oral delivery system of cannabinoids: Pharmacokinetic evaluation in healthy volunteers in comparison to buccal spray administration. | Cherniakov I et al. | β | 2017 | β |
| The effect of Pro NanoLipospheres (PNL) formulation containing natural absorption enhancers on the oral bioavailability of delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) in a rat model. | Cherniakov I et al. | β | 2017 | β |
| The genetic epidemiology of substance use disorder: A review. | Prom-Wormley EC et al. | β | 2017 | β |
| ABC transporters P-gp and Bcrp do not limit the brain uptake of the novel antipsychotic and anticonvulsant drug cannabidiol in mice. | Brzozowska N et al. | β | 2016 | β |
| Cetuximab increases concentrations of irinotecan and of its active metabolite SN-38 in plasma and tumour of human colorectal carcinoma-bearing mice. | Chu C et al. | β | 2014 | β |
| Control of spasticity in a multiple sclerosis model using central nervous system-excluded CB1 cannabinoid receptor agonists. | Pryce G et al. | β | 2014 | β |
| Enhanced brain disposition and effects of Ξ9-tetrahydrocannabinol in P-glycoprotein and breast cancer resistance protein knockout mice. | Spiro AS et al. | β | 2012 | β |
| Genetic association study of the P300 endophenotype in schizophrenia. | Decoster J et al. | β | 2012 | β |
| Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model. | Lin X et al. | β | 2011 | β |
| Interaction of drugs of abuse and maintenance treatments with human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2). | Tournier N et al. | β | 2010 | β |
| Association between ABCB1 C3435T polymorphism and increased risk of cannabis dependence. | Benyamina A et al. | β | 2009 | β |
| Disposition of everolimus in mdr1a-/1b- mice and after a pre-treatment of lapatinib in Swiss mice. | Chu C et al. | β | 2009 | β |
| Interindividual variation in the pharmacokinetics of Delta9-tetrahydrocannabinol as related to genetic polymorphisms in CYP2C9. | Sachse-Seeboth C et al. | β | 2009 | β |